SCHEMBL6598569

SCHEMBL6598569

OCc1ccc2ncoc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
KMT2A Q03164 1/20 0.47
DYRK1A Q13627 2/20 0.45
LMNA P02545 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
NAMPT P43490 1/20 0.38
RECQL P46063 1/20 0.37
CTNNB1 P35222 1/20 0.36
WNT3A P56704 1/20 0.36
CA12 O43570 1/20 0.36
CA2 P00918 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2358986 0.85 MEN1 (0.65) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL3815115 0.81 DYRK1A (0.45) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL2621292 0.81 LMNA (0.48) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL355077 0.81 DYRK1A (0.49) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL353595 0.81 DYRK1A (0.45) MEN1ALDH1A1GAAKMT2ADYRK1A
Hydrochloric Acid SCHEMBL29585867 0.79 DYRK1A (0.47) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL20041206 0.79 GAA (0.77) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL8221522 0.78 LMNA (0.49) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL5548267 0.78 DYRK1A (0.42) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL28063797 0.78 MEN1 (0.45) MEN1ALDH1A1GAAKMT2ADYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-10-12 US disclosed
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-10-12 US disclosed
CN-116507326-A Compounds as GLP-1R agonists 拓臻制药公司 2023-07-28 CN disclosed
WO-2022040600-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. (US) 2022-02-24 WO disclosed
EP-1385833-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS Amgen Inc. (US) 2004-02-04 EP disclosed
WO-2002083654-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS AMGEN INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS GLP1R, GIPR, GCGR MEN1 735/4885ALDH1A1 3522/4885GAA 563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.